labetalol has been researched along with alprenolol in 26 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (23.08) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (42.31) | 29.6817 |
2010's | 9 (34.62) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Faller, B; Wohnsland, F | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
Baker, JG | 1 |
Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Akamatsu, M | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Aggerbeck, M; Guellaen, G; Hanoune, J | 1 |
Chimura, T | 1 |
Fishbein, L; Jackson, CD | 1 |
Dean, S; Jack, DB; Kendall, MJ; Laugher, S | 1 |
Bengtsson, C | 1 |
Hvidt, S; Kjaer, K; Kofod, P; Vejlø, S | 1 |
Ikonen, M; Kontturi, K; Murtomäki, L | 1 |
Bao, J; Johnson, PE; Krylov, SN; Krylova, SM; Reinstein, O; Wilson, DJ | 1 |
Andresen, BT; Chang, A; Chen, S; Cleveland, KH; Guo, L; Huang, KM; Huang, Y; Liang, S | 1 |
1 review(s) available for labetalol and alprenolol
Article | Year |
---|---|
A toxicological review of beta-adrenergic blockers.
Topics: Acebutolol; Adrenergic beta-Antagonists; Alprenolol; Animals; Atenolol; Cocarcinogenesis; Ethanolamines; Female; Kinetics; Labetalol; Lethal Dose 50; Male; Metoprolol; Mice; Mutagens; Nadolol; Neoplasms, Experimental; Oxprenolol; Pindolol; Practolol; Propanolamines; Propranolol; Rats; Sotalol; Timolol | 1986 |
1 trial(s) available for labetalol and alprenolol
Article | Year |
---|---|
Labetalol and alprenolol. A comparative investigation of antihypertensive effect.
Topics: Adult; Aged; Alprenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged | 1980 |
24 other study(ies) available for labetalol and alprenolol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Biochemical evidence for the dual action of labetalol on alpha- and beta-adrenoceptors.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Alprenolol; Animals; Cell Membrane; Dihydroergotoxine; Epinephrine; Ethanolamines; Female; In Vitro Techniques; Labetalol; Liver; Myocardium; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1978 |
[Effects of beta-adrenoceptor blockade on parturition and fetal cardiovascular and metabolic system].
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Blood Glucose; Ethanolamines; Female; Fetal Death; Fetal Heart; Fetus; Labetalol; Labor, Obstetric; Maternal-Fetal Exchange; Pregnancy; Rats; Rats, Inbred Strains; Regional Blood Flow; Uterine Contraction; Uterus | 1985 |
Detection of some antihypertensive drugs and their metabolites in urine by thin-layer chromatography: II. A further five beta blockers and dihydralazine.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Chromatography, Thin Layer; Dihydralazine; Humans; Hypertension; Labetalol; Sotalol | 1980 |
Impairment of physical performance after treatment with beta blockers and alpha blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Alprenolol; Heart Rate; Humans; Hydrochlorothiazide; Labetalol; Male; Metoprolol; Physical Exertion; Pindolol; Prazosin; Propranolol; Running | 1984 |
Microcalorimetric and zeta potential study on binding of drugs on liposomes.
Topics: Algorithms; Alprenolol; Binding Sites; Binding, Competitive; Calorimetry; Entropy; Kinetics; Labetalol; Liposomes; Models, Chemical; Molecular Structure; Pharmaceutical Preparations; Phosphatidylcholines; Phosphatidylglycerols; Propranolol; Tetracaine; Thermodynamics | 2010 |
Kinetic capillary electrophoresis with mass-spectrometry detection (KCE-MS) facilitates label-free solution-based kinetic analysis of protein-small molecule binding.
Topics: Alprenolol; Electrophoresis, Capillary; Kinetics; Labetalol; Mass Spectrometry; Orosomucoid; Pindolol; Propranolol; Protein Binding; Proteins; Small Molecule Libraries | 2011 |
Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Carvedilol; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Epidermal Growth Factor; Inhibitory Concentration 50; Labetalol; Ligands; Mice; Mice, Inbred C57BL; Receptors, Adrenergic; Receptors, Adrenergic, beta; RNA, Small Interfering; Signal Transduction; Skin; Skin Neoplasms; Ultraviolet Rays | 2019 |